Titre:
  • S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma
Auteur:Bachet, Jean-Baptiste; Marechal, Raphaël; Demetter, Pieter; Bonnetain, Franck; Cros, Jérôme; Svrcek, Magali; Bardier-Dupas, Armelle; Hammel, Pascal; Sauvanet, Alain; Louvet, Christophe; Paye, François; Vaillant, Jean-Christophe; André, Thierry; Closset, Jean; Salmon, Isabelle; Emile, Jean-François; Van Laethem, Jean-Luc
Informations sur la publication:European journal of cancer, 49, 12, page (2643-2653)
Statut de publication:Publié, 2013-08
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Adjuvant therapy
Gemcitabine
Pancreatic adenocarcinoma
S100A2
MeSH keywords:Adenocarcinoma -- drug therapy -- metabolism -- pathology -- surgery
Adult
Aged
Aged, 80 and over
Chemotactic Factors -- analysis
Chemotherapy, Adjuvant
Combined Modality Therapy
Disease-Free Survival
Female
Humans
Immunohistochemistry
Lymphatic Metastasis
Male
Middle Aged
Multivariate Analysis
Neoplasm Recurrence, Local
Outcome Assessment (Health Care) -- statistics & numerical data
Pancreatic Neoplasms -- drug therapy -- metabolism -- surgery
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Retrospective Studies
S100 Proteins -- analysis
Tumor Markers, Biological -- analysis
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0959-8049
info:doi/10.1016/j.ejca.2013.04.017
info:pii/S0959804913003511
info:scp/84879912056
info:pmid/23726265